{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:26:31Z","timestamp":1793953591380,"version":"4.8.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00780-2","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:53:29Z","timestamp":1756115609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Factors associated with viral load suppression among children and adolescents on dolutegravir-based antiretroviral regimen in Tanzania: a longitudinal analysis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6952-2399","authenticated-orcid":false,"given":"Abdallah Abtwalibe","family":"Maghembe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion Sumari-de","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-0559","authenticated-orcid":false,"given":"Mtoro J.","family":"Mtoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Johnson","family":"Mahande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"780_CR1","unstructured":"WHO. World Health Organization (WHO) recommends. dolutegravir as preferred HIV treatment option in all populations. 2021 [cited 2022 Jan 10]. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations"},{"key":"780_CR2","unstructured":"UNAIDS. United Republic of Tanzania, HIV and AIDS estimates. 2024 [cited 2025 Jun 26]. http:\/\/www.unaids.org\/en\/regionscountries\/countries\/unitedrepublicoftanzania\/."},{"key":"780_CR3","unstructured":"National Bureau of Statistics. Tanzania HIV Impact Survey (THIS) 2016\u20132017. Tanzania HIV Impact Surv 2016\u20132017. 2018;2016\u20137. https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2019\/06\/FINAL_THIS-2016-2017_Final-Report__06.21.19_for-web_TS.pdf"},{"key":"780_CR4","first-page":"139","volume":"176","author":"S Shantanam","year":"2018","unstructured":"Shantanam S. Safety, tolerability and efficacy of generic dolutegravir (DTG) containing ART regimen among South Indian HIV-infected patients. Clin Infect Dis. 2018;176:139\u201348.","journal-title":"Clin Infect Dis"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2147\/HIV.S316776","volume":"13","author":"EA Mehari","year":"2021","unstructured":"Mehari EA, Muche EA, Gonete KA. Virological suppression and its associated factors of dolutegravir based regimen in a resource-limited setting: an observational retrospective study in Ethiopia. HIV\/AIDS - Res Palliat Care. 2021;13:709\u201317.","journal-title":"HIV\/AIDS - Res Palliat Care"},{"key":"780_CR6","unstructured":"Briand C, Dollfus C, Caseris M, Kantor E, Avettand-f\u00e8no\u00ebl V, Descamps D et al. Dolutegravir based cART in Vertically-HIV-1-Infected adolescents in Real-Life setting. J Int AIDS Soc. 2016;812."},{"key":"780_CR7","first-page":"52","volume":"26","author":"P Harcourt","year":"2020","unstructured":"Harcourt P, Paul NI, Ugwu RO. Dolutegravir (DTG) based fixed dose combination (FDC) of Tenofovir \/ Lamivudine \/ Dolutegravir (TLD) and viral load suppression in children in. J Sci Res Rep. 2020;26:52\u20139.","journal-title":"J Sci Res Rep"},{"key":"780_CR8","doi-asserted-by":"publisher","unstructured":"Rolle CP, Nguyen V, Hinestrosa F, Dejesus E. Virologic outcomes of switching to dolutegravir functional mono\u2013 or dual therapy with a non\u2013 cytosine nucleoside analog: a retrospective study of treatment\u2013 experienced, patients living with HIV. AIDS Res Ther. BioMed Central; 2021;18:26. https:\/\/doi.org\/10.1186\/s12981-021-00352-0","DOI":"10.1186\/s12981-021-00352-0"},{"key":"780_CR9","doi-asserted-by":"crossref","unstructured":"Tsikhutsu I, Bii M, Dear N, Ganesan K, Kasembeli A, Sing\u2019oei V et al. Prevalence and correlates of viral load suppression and human immunodeficiency virus (HIV) drug resistance among children and adolescents in South rift Valley and kisumu, Kenya. Clin Infect Dis. 2022;1\u20139.","DOI":"10.1093\/cid\/ciac059"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/aid.2020.0196","volume":"37","author":"D Carlo","year":"2021","unstructured":"Carlo D, Di, Falasca F, Palermo E, Mezzaroma I, Fimiani C, Siccardi G, et al. Dolutegravir-Based regimen for maintenance of viral suppression in people living with HIV: 48-week results in real-life setting. AIDS Res Hum Retroviruses. 2021;37:478\u201385.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"780_CR11","first-page":"27","volume":"19","author":"V Soriano","year":"2014","unstructured":"Soriano V, Labarga P, Bisallah CI, Ochigbo M, Muhammad O, Sulaiman B, et al. Effectiveness of dolutegravir (DTG), an HIV integrase inhibitor in improving viral load suppression among HIV Inf IOSR. J Dent Med Sci. 2014;19:27\u201332.","journal-title":"J Dent Med Sci"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050312116675813","volume":"4","author":"S Waqas","year":"2016","unstructured":"Waqas S, Connor MO, Levey C, Mallon P, Sheehan G, Patel A, et al. Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care university hospital in Ireland. SAGE Open Med. 2016;4:1\u20133.","journal-title":"SAGE Open Med"},{"key":"780_CR13","doi-asserted-by":"publisher","unstructured":"Ndashimye E, Arts EJ. International Journal of Infectious Diseases Dolutegravir response in antiretroviral therapy na\u00efve and experienced patients with M184V \/ I: impact in low-and middle-income settings. Int J Infect Dis. International Society for Infectious Diseases; 2021;105:298\u2013303.: https:\/\/doi.org\/10.1016\/j.ijid.2021.03.018","DOI":"10.1016\/j.ijid.2021.03.018"},{"key":"780_CR14","doi-asserted-by":"crossref","unstructured":"Lambert-niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard J et al. INSTI-Based triple regimens in Treatment-Na\u00efve HIV- infected patients are associated with HIV-RNA viral load suppression at ultralow levels. Open Forum Infect Dis. 2019;1\u20139.","DOI":"10.1093\/ofid\/ofz177"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/ijstd.IJSTD_34_20","volume":"42","author":"AK Patel","year":"2021","unstructured":"Patel AK, Patel KK, Pujari1 S, Patel JK. Kumar3 A. Virological outcome and frequency of low\u2013 level viremia in patients receiving generic dolutegravir\u2013 containing regimen at a large tertiary care clinic in Western India. Indian J Sex Transm Dis AIDS. 2021;42:31\u20137.","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/cid\/cix1083","volume":"66","author":"BO Taiwo","year":"2018","unstructured":"Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, et al. MAJOR ARTICLE ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency Virus-1 (HIV-1)\u2013 infected participants with HIV-1 RNA\u2009<\u2009500 000 Copies \/ mL. Clin Infect Dis. 2018;66:1689\u201397.","journal-title":"Clin Infect Dis"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting Dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70:1267\u201374.","journal-title":"Clin Infect Dis"},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s12098-017-2441-y","volume":"84","author":"R Singh","year":"2017","unstructured":"Singh R, Mukherjee A, Singla M, Das BK, Kabra SK, Lodha R. Immunological and virological responses to highly active antiretroviral therapy in HIV-1 infected children. Indian J Pediatr Indian J Pediatr. 2017;84:893\u20136.","journal-title":"Indian J Pediatr Indian J Pediatr"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.25272","volume":"22","author":"JM Humphrey","year":"2019","unstructured":"Humphrey JM, Genberg BL, Keter A, Musick B, Gardner A, Hogan JW, et al. Viral suppression among children and their caregivers living with HIV in Western Kenya. J Int AIDS Soc. 2019;22:1\u201310.","journal-title":"J Int AIDS Soc"},{"key":"780_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.physbeh.2017.03.040","volume":"176","author":"ME Levy","year":"2017","unstructured":"Levy ME, Griffith C, Ellenberger N, Monroe AK, Castel AD, Rakhmanina N. Outcomes of integrase Inhibitor-Based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents, and young adults with HIV infection. Physiol Behav. 2017;176:139\u201348.","journal-title":"Physiol Behav"},{"key":"780_CR21","doi-asserted-by":"publisher","unstructured":"Id TA, Takarinda KC, Phillips A, Ndhlovu C. Provision of HIV viral load testing services in Zimbabwe: Secondary data analyses using data from health facilities using the electronic Patient Monitoring System. PLoS One. 2021;16:1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0245720","DOI":"10.1371\/journal.pone.0245720"},{"key":"780_CR22","unstructured":"Ahmed B, Elashi Y. Determinants of viral suppression among adolescents on antiretroviral therapy in Thabo Mofutsanyane district municipality, free state province, South Africa. Afr J AIDS Res. 2021;37."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00780-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00780-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:48:32Z","timestamp":1757483312000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00780-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00780-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6641179\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Kilimanjaro Christian Medical University College of Tumaini University Makumira ethical committee (No: PG 12\/2021). Administrative approval was obtained from the Ministry of Health, Community Development, Elderly and Children (Ref. No PA. 87\/266\/02-A\/97). The study was conducted under the 1964 Declaration of Helsinki and its later amendments. As the study utilized secondary data from routinely collected program data, informed consent was waived by the ethical committee. All patient data were de-identified prior to analysis to maintain confidentiality and participant codes from CTC identity numbers were used instead of names.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"82"}}